International NewsMedical ScienceScience

Cure for Cancer Found Claims Israeli Bio Tech Firm

Medicine will have Minimum Side Effects and might be available in 2020


A cure for Cancer Found?

At a time when cancer is spreading day by day at a fast pace across the globe, an Israeli biotech
the company has claimed that they will have the treatment for this deadly disease by 2020.

According to the company’s spokesperson, cancer treatment will be helpful from the very first day and will last for only some weeks. Moreover, their medicines will have no or minimal side-effects. He further added that the cure for cancer will be offered at a much lower cost than other treatments presented in the market.

But Accelerated Evolution Biotechnologies Ltd (AEBi), found in 2000 from the ITEK Weizmann
technology incubator has made strong claims to treat the disease completely.

The Cure which the biotech company calls MuTaTo (multi-target toxin) is based on SoAP technology,
which belongs to the phage show group of technologies.

CEO of the biotech company Dr. Ilan Morad told they started with identifying why other cancer-related
drugs and cure are not working then they looked for a helpful way to counter it.

Most cancer medicine attacks a particular target or on the cancer cell, but MuTaTo attack the
cancer cells receptors from three different directions.

“In its place of attacking receptors one at a time, we attack receptors three at a time. Not even
cancer can change three receptors at one time said Morad, to the daily newspaper.

After a successful rats trail, Morad said that the company is now getting ready to try medicines on
humans through this year. Following this, they will commence the medicine in the market by next

The claim made by the biotech company sounds very motivating when around 18. 1 million new cases
of cancer are being diagnosed every year across the world.

To read more about the interesting content stay tuned to

You can also follow us on Facebook, Linkedin, and Instagram.

Leave a Reply

%d bloggers like this: